With Brexit and the new EU Falsified Medicine Directive, what does the future hold for parallel trade? Over 90 senior leaders in parallel trade will meet in London in February 2017 to discuss upcoming trends and share best practices.
The Falsified Medicines Directive introduces tough directives to improve the protection of public health with new pan-European measures to ensure that medicines are safe and that the trade in medicines is strictly controlled. Falsified medicines (the term "falsified" is used to distinguish the issue from IP violations, so-called "counterfeits") are a major threat to public health and safety. As falsifications become more sophisticated, the risk that falsified medicines reach patients in the EU increases every year. Falsified medicines represent a serious threat to global health and call for a comprehensive strategy both at European and international level. (Source: European Commission)*
Dr Rick Greville, Director Wales and Director Distribution & Supply, The Association of the British Pharmaceutical Industry, will be speaking on "The European Commission's Falsified Medicines Directive (FMD) - Recent Update" at SMi Group's Parallel Trade 2017 conference, taking place in London on the 6th and 7th of February.
Dr. Greville will discuss what progress has been made since February 2016, what the market participants need to know about "product information templates", what are the regulatory requirements for nationally authorised products and much more.
Further information on this presentation and the conference programme is available at www.parallel-trade.com/MedicalNewsToday
Parallel Trade for Pharma conference, organised by the SMi Group, will be returning to London in February 2017, for its 11th year. This meeting will bring 90+ selected senior leaders in parallel trade to discuss upcoming trends and share best practices, short term and long term concerns of pharma manufacturers, regulators and parallel traders.
Other key topics to be discussed during the 2-day conference are: Pharmaceutical anti-counterfeiting - Combating the danger from fake drugs, Regional focus - From Germany to Eurasia, Legal view - Intellectual property, competition and regulatory challenges, The future of parallel trade, New trends and their impact on parallel trade and so much more.
The event programme also features three panel debates on: Shortages; Challenges and opportunities for parallel traders; Technology & new trends; and two exclusive post conference workshops on "Understanding IP and competition law issues in parallel trade" (Hosted by Kathy Osgerby, Associate and Karoline Zwierzynska, Associate, Arnold & Porter (UK) LLP) and "Parallel Trade - Management Strategies" (Hosted by Janice Haigh, Practice Leader, Market Access, Quintiles).
For further information please refer to www.parallel-trade.com/MedicalNewsToday
Expert Speakers Line up for 2017 includes: The Association of the British Pharmaceutical Industry (Dr Rick Greville, Director Distribution & Supply), Shire International GmbH (Eric Noehrenberg, Director, Regional Market Access Lead, Latin America), Delfarma (Tomasz Dzitko, President), European Association for Euro-Pharmaceutical Companies (Heinz Kobelt, Director European Affairs), ISPOR (Vladimir Zah, Health Economics Consultant), Abacus Medicine (Flemming Wagner, CEO), IMS Health (Alexey Savin, Principal Russia and CIS), Arnold & Porter (UK) LLP (Kathy Osgerby, Associate, and Karoline Zwierzynska, Associate), Europe Economics (Dermot Glynn, Senior Advisor), European Alliance for Access to Save Medicines (Mike Isles, Executive Director), Research Health (Dr Andrew Stainthorpe, Director Market Access and Managed Entry) and many more.
The complete 2-day event programme is available for complimentary download at www.parallel-trade.com/MedicalNewsToday
Latest confirmed attendees include senior representatives from MHRA, AbbVie Deutschland GmbH & Co. KG, Astellas Pharma, AstraZeneca, Teva UK, Vifor Pharma, Janssen Pharmaceutica NV, Napp Laboratories, Ratiopharm GmbH, Kantar Health, Ferring Pharmaceuticals, LEO Pharma, AstraZeneca Czech Republic, Swedish Orphan Biovitrum AB, Amgen, Novartis Pharmaceuticals, Novartis Turkey, LEO Pharma, Johnson & Johnson, Novo Nordisk Pharma, Daiichi Sankyo Europe GmbH, Sunovion Pharmaceuticals Europe Ltd and many more.
Feedback from past attendees of SMi Group's Parallel Trade: "Interesting conference, generating a good debate from all sides", "Great conference! Audience very enthusiastic and actively participating in discussions", "Very good discussing about pricing issues and competition", "Overall, a very positive experience!", "The best Parallel Trade conference of the last 5 years!".